Holen Sie sich die Stockscreener-App
60.63
3.48%
2.04
Schlusskurs vom Vortag:
$58.59
Offen:
$58.71
24-Stunden-Volumen:
940.57K
Relative Volume:
1.08
Marktkapitalisierung:
$2.82B
Einnahmen:
$1.35B
Nettoeinkommen (Verlust:
$163.34M
KGV:
18.51
EPS:
3.2763
Netto-Cashflow:
$189.17M
1W Leistung:
+5.44%
1M Leistung:
-15.99%
6M Leistung:
+14.14%
1J Leistung:
-5.40%
1-Tages-Spanne:
$58.43
$60.78
1-Wochen-Bereich:
$55.95
$60.78
52-Wochen-Spanne:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Firmenname
Haemonetics Corp
Sektor
Branche
Telefon
(781) 848-7100
Adresse
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
60.63 | 2.72B | 1.35B | 163.34M | 189.17M | 3.2763 |
|
ABT
Abbott Laboratories
|
113.29 | 195.21B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
377.32 | 141.28B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
98.49 | 123.60B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
76.28 | 113.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.98 | 45.52B | 6.07B | 1.06B | 799.60M | 1.8527 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Herabstufung | Needham | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Bestätigt | Barrington Research | Outperform |
| 2025-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-06-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-02-07 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Eingeleitet | CL King | Buy |
| 2024-09-11 | Eingeleitet | BofA Securities | Neutral |
| 2024-09-10 | Eingeleitet | BTIG Research | Buy |
| 2024-06-12 | Hochstufung | Needham | Hold → Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-01-27 | Herabstufung | Needham | Buy → Hold |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-17 | Fortgesetzt | Raymond James | Outperform |
| 2021-06-17 | Eingeleitet | Citigroup | Buy |
| 2021-05-14 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Eingeleitet | Needham | Buy |
| 2019-08-07 | Bestätigt | Barrington Research | Outperform |
| 2019-05-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Bestätigt | Barrington Research | Outperform |
| 2018-08-09 | Bestätigt | Barrington Research | Outperform |
| 2018-02-07 | Bestätigt | Barrington Research | Outperform |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Bestätigt | Barrington Research | Outperform |
| 2017-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Bestätigt | The Benchmark Company | Hold |
| 2016-09-20 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-08-02 | Bestätigt | Jefferies | Buy |
| 2016-08-02 | Bestätigt | The Benchmark Company | Hold |
Alle ansehen
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
Haemonetics Corporation $HAE Stock Holdings Lessened by Heartland Advisors Inc. - MarketBeat
ABN Amro Investment Solutions Buys Shares of 200,000 Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation (HAE) Q3 Performance Prompts Baird Model Update, Price Target Falls to $81 - Finviz
Growth Recap: Will Haemonetics Corporation outperform its industry peersJuly 2025 EndofMonth & Long-Term Safe Return Strategies - baoquankhu1.vn
Assessing Haemonetics (HAE) Valuation After Recent Share Price Weakness - Yahoo Finance
A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness - simplywall.st
Strong Competitive Position Drove Haemonetics Corporation’s (HAE) Earnings Growth - Yahoo Finance
Short Interest in Haemonetics Corporation (NYSE:HAE) Decreases By 21.7% - MarketBeat
Haemonetics Corporation $HAE Shares Sold by Principal Financial Group Inc. - MarketBeat
Haemonetics Releases 2024-2025 Corporate Responsibility Report - The Globe and Mail
Haemonetics (HAE) Balances Softer Interventional Sales With Buybacks – What Story Does Guidance Tell? - simplywall.st
5 Revealing Analyst Questions From Haemonetics's Q4 Earnings Call - Finviz
5 Revealing Analyst Questions From Haemonetics’s Q4 Earnings Call - Yahoo Finance
Skylands Capital LLC Has $3.97 Million Stock Holdings in Haemonetics Corporation $HAE - MarketBeat
Haemonetics (HAE) International Revenue Performance Explored - Yahoo Finance
Key Players in the Autotransfusion Systems MarketHaemonetics - openPR.com
Chuck Royce's Strategic Moves: Significant Reduction in Haemonetics Corp - Yahoo Finance
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term - Yahoo Finance
A Quick Look at Today's Ratings for Haemonetics(HAE.US), With a Forecast Between $75 to $94 - 富途牛牛
Haemonetics raises fiscal 2026 guidance as plasma and blood management drive 8%-10% organic growth outlook - MSN
Haemonetics Earnings Call: Strong Core, IVT Drag - TipRanks
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Haemonetics (HAE) and Denali Therapeutics (DNLI) - The Globe and Mail
Why Haemonetics (HAE) Raised 2026 Guidance After Strong Plasma And Tech Results And What It Signals - Yahoo Finance
Haemonetics (HAE) Margin Strength In Q3 2026 Reinforces Earnings Led Bullish Narratives - simplywall.st
Haemonetics Q3 Earnings Call Highlights - MarketBeat
Haemonetics (NYSE:HAE) Trading Down 5.6%Here's What Happened - MarketBeat
Haemonetics stock slides 7% as revenue dip and hospital softness blunt raised outlook - TechStock²
Citigroup Lowers Price Target for Haemonetics (HAE) to $75 | HAE Stock News - GuruFocus
Mizuho Lowers Haemonetics (HAE) Price Target, Maintains Outperfo - GuruFocus
Haemonetics (HAE) Rating Update: Barrington Research Raises Pric - GuruFocus
Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips - Yahoo Finance
Haemonetics' (HAE) "Buy" Rating Reaffirmed at BTIG Research - MarketBeat
Haemonetics Corporation (NYSE:HAE) Q3 2026 Earnings Call Transcript - Insider Monkey
Haemonetics price target raised to $94 from $93 at Barrington - TipRanks
Haemonetics (HAE) Valuation Check After Q3 Beat And Higher 2026 Guidance - simplywall.st
HAE Q4 Deep Dive: Plasma Momentum and Hospital Weakness Shape Mixed Results - Finviz
Haemonetics Q3 2026 slides: Margin expansion and cash flow surge despite revenue transition By Investing.com - Investing.com South Africa
Haemonetics stock maintains Market Outperform rating at Citizens on strong plasma growth - Investing.com Nigeria
Haemonetics stock maintains Market Outperform rating at Citizens on strong plasma growth By Investing.com - Investing.com South Africa
BTIG Reiterates Buy Rating and $88 Price Target on HAE | HAE Sto - GuruFocus
Baird lowers Haemonetics stock price target to $81 on mixed outlook By Investing.com - Investing.com South Africa
Baird lowers Haemonetics stock price target to $81 on mixed outlook - Investing.com Nigeria
Decoding Haemonetics Corp (HAE): A Strategic SWOT Insight - GuruFocus
Haemonetics Q3 2026 slides: Margin expansion and cash flow surge despite revenue transition - Investing.com Canada
Haemonetics (NYSE:HAE) Announces Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Haemonetics Corp (HAE) Q3 2026 Earnings Call Highlights: Strong - GuruFocus
Haemonetics reports Q3 adjusted EPS $1.31, consensus $1.25 - TipRanks
Haemonetics HAE Q3 2026 Earnings Call Transcript - The Globe and Mail
Haemonetics (HAE) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Haemonetics (HAE) Exceeds Q3 Revenue Expectations with Strong Pe - GuruFocus
Haemonetics's (NYSE:HAE) Q4 CY2025 Sales Top Estimates, Stock Soars - Finviz
Finanzdaten der Haemonetics Corp-Aktie (HAE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):